论文部分内容阅读
目的考察夏佛塔苷对高脂饮食诱导C57BL/6小鼠胆囊胆固醇结石形成的影响。方法将72只雄性C57BL/6小鼠随机分成正常对照组,模型组,熊去氧胆酸组,夏佛塔苷低、中、高剂量组(20,40,80 mg·kg~(-1)),每组12只,灌胃给药8周。除正常对照组外,其余各组均采用高脂饲料喂养8周建立胆囊胆固醇结石模型。每隔7 d记录小鼠体质量和平均进食量;肉眼观察和显微镜观察结石形成情况;检测血清中总胆固醇(TC),高密度脂蛋白胆固醇(HDL-C),低密度脂蛋白胆固醇(LDL-C),总胆汁酸(TBA),甘油三酯(TG)的水平;检测胆汁中TC,TBA,磷脂(PL)水平并分析胆固醇饱和指数(CSI)的变化;观察肝脏病理组织形态学变化。结果与模型组比较,夏佛塔苷高剂量组能较显著降低成石率(33.3%),升高血清中的HDL-C水平(P<0.05),降低TG水平(P<0.05)。显著降低胆囊胆汁中TC、PL的含量,升高TBA的含量,进而降低CSI(均P<0.01)。明显的减轻肝脏脂肪变性。结论夏佛塔苷能够抑制高胆固醇饲料诱导C57BL/6小鼠胆囊胆固醇结石形成,其可能与降低胆囊胆汁CSI水平和升高血液中HDL-C水平,改善肝脏脂质代谢异常导致损伤相关。
Objective To investigate the effects of summeroside on the formation of gallstone in gallbladder in C57BL / 6 mice induced by high fat diet. Methods Seventy-two male C57BL / 6 mice were randomly divided into normal control group, model group, ursodeoxycholic acid group, low, middle and high dose of alystatin group (20, 40, 80 mg · kg -1 )), Each group of 12, gavage for 8 weeks. Except normal control group, the other groups were fed with high-fat diet for 8 weeks to establish gallbladder cholesterol stone model. The body weight and average food intake of mice were recorded every 7 days. The formation of calculus was observed by macroscopy and microscope. The levels of total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (TC), total bile acid (TBA) and triglyceride (TG) were measured. The level of TC, TBA and phospholipid (PL) in bile were detected and the change of cholesterol saturation index (CSI) . Results Compared with the model group, the high-dose paclitaxin significantly reduced the rate of stone formation (33.3%), raised the level of serum HDL-C (P <0.05) and decreased the level of TG (P <0.05). The content of TC and PL in gallbladder bile decreased significantly, and the content of TBA increased, which decreased CSI (all P <0.01). Significantly reduce liver steatosis. CONCLUSIONS: Clozapyl can inhibit the cholesterol gallstone-induced gallstone formation in C57BL / 6 mice, which may be related to the reduction of the level of bile-cholesterol in the gallbladder and the increase of HDL-C level in the blood, and to the improvement of liver dyslipidemia.